6L9.F ViewRay XETRA up 2400% to €0.025 on 27 Mar 2026: next price signals

The 6L9.F stock of ViewRay, Inc. jumped 2400.0% to €0.025 on XETRA on 27 Mar 2026, driven by a sudden spike in trade volume. This move came from a low open of €0.001 and a day high of €0.025, with 3,500 shares traded versus an average volume of 279. The market closed with a pronounced relative volume surge of 12.54x, making ViewRay a top high-volume mover on the Germany XETRA session. We examine drivers, fundamentals, risks and a Meyka AI model forecast to frame next price signals for traders and investors.

6L9.F stock movers: price and volume snapshot

ViewRay, Inc. (6L9.F) closed at €0.025 on XETRA in Germany on 27 Mar 2026, a change of €0.024, or 2400.0%, from the previous close. The session traded 3,500 shares versus an average of 279 shares. The one-day range was €0.001 to €0.025 and the company’s market cap on this price reads approximately €207,228,256. This headline spike qualifies 6L9.F stock as a high-volume mover for the session and warrants short-term attention from active traders.

What likely drove the jump in 6L9.F stock

The immediate driver appears to be concentrated retail or block trading into a very thinly traded listing, given the sharp gap from €0.001 to €0.025 and the low absolute volume. There is no new SEC-style earnings release in the dataset, so price action likely reflects liquidity squeezes, trading interest in micro-cap healthcare names, or re-listing flows. Sector context shows healthcare med-dev names can behave erratically on sparse liquidity, amplifying price moves for 6L9.F stock.

Fundamental snapshot for ViewRay, Inc. and valuation metrics

ViewRay is a U.S.-based medical devices company that makes MRI-guided radiation therapy systems. Key trailing metrics: EPS -0.55, PE -0.05, price-to-book 0.06, and current ratio 2.36. Revenue per share TTM is 0.566 and book value per share is 0.455. Debt-to-equity is 1.05, and cash per share is 0.752. These figures show a loss-making med-tech with meaningful balance-sheet cash, but substantial operating losses. Fundamental valuation supports caution for long-term investors in 6L9.F stock.

Technical context, sector performance and Meyka grade

On technical averages, 6L9.F trades well below the 50-day average €0.319 and the 200-day average €2.717, indicating a multi-month downtrend followed by sporadic spikes. The Healthcare sector has mixed performance; med-dev peers trade at materially higher price-to-book multiples. Meyka AI rates 6L9.F with a score out of 100: 61.27 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Grades are informational only and not investment advice.

Risks and catalysts for 6L9.F stock

Primary risks are extreme liquidity volatility, continued operating losses, and debt levels with debt-to-equity at 1.05. Catalysts that could reprice the stock include clinical wins, equipment orders, formal earnings updates, or a change in listing status. Given the tiny absolute price and elevated historical highs at €4.60, price action can swing dramatically. Traders in 6L9.F stock should apply strict risk controls and position size limits.

Trading strategy and actionable signals for short-term traders

For high-volume mover setups, traders should watch intraday volume confirmations and time-price consolidation above €0.010 as a minimum support signal. If volume decays, expect reversion toward the prior levels near €0.001–€0.005. Limit orders and very tight stop losses are recommended for scalps. Institutional-style investing is risky until fundamentals improve; for speculative positions, plan exits at predefined price targets and keep exposure small.

Final Thoughts

Key takeaways on 6L9.F stock: the session close at €0.025 on XETRA on 27 Mar 2026 marked a 2400.0% spike driven by a liquidity event in a thin market. Fundamentals show ViewRay as loss-making with EPS -0.55 and a price-to-book of 0.06, supporting a cautious stance for long-term investors. Meyka AI’s forecast model projects a 12-month base target of €0.050, implying an upside of 100.00% from the current €0.025, with a conservative range of €0.020 and a bull case of €0.200. Forecasts are model-based projections and not guarantees. Given extreme volatility and low float, traders should size positions carefully and treat 6L9.F stock as high-risk speculation rather than a core holding. For more company details see the official site and our Meyka page for continuous real-time signals: ViewRay and ViewRay 6L9.F on Meyka.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.